Bridging clinical investigators and statisticians: Writing the statistical methodology for a research proposal

Journal of Investigative Medicine

Volumn 57, Issue 8, 2009, Pages 818-824

  Adams Huet, Beverley ^a   Ahn, Chul ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biostatistics; Clinical research; Protocol; Research proposal; Statistical methods; Statistician; Study design

Indexed keywords

CLINICAL RESEARCH; DATA ANALYSIS; METHODOLOGY; OUTCOMES RESEARCH; PLANNING; RANDOMIZATION; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS;

HUMANS; INTERPROFESSIONAL RELATIONS; RESEARCH DESIGN; RESEARCH PERSONNEL; WRITING;

EID: 74249102641     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181c2996c     Document Type: Review

References (21)

1. Altman DG, Goodman SN, Schroter S. How statistical expertise is used in medical research. JAMA. 2002;287:2817-2820.
2. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1993;270:2598-2601.
3. American Statistical Association. Ethical guidelines for statistical practice: executive summary. Amstat News. April 1999:12-15.
4. Lenth RV. Some practical guidelines for effective sample size determination. Am Stat. 2001;55:187-193.
5. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-128. Available at: http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize. Accessed October 19, 2009.
6. Ahn C, Jung SH. Effect of dropouts on sample size estimates for test on trends across repeated measurements. J Biopharm Stat. 2005;15:33-41.
7. Ahn C. Sample size requirement for clinical trials with repeated binary outcomes. Drug Inf J. 2008;42:107-113.
8. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10:307-312.
9. Pocock S. Clinical Trials: A Practical Approach. New York, NY: John Wiley & Sons; 1983.
10. Day SJ, Altman DG. Statistics notes: blinding in clinical trials and other studies. BMJ. 2000;321:504.
11. International Conference on Harmonisation (ICH). Guidance for Industry: E9 Statistical Principles for Clinical Trials. Rockville, MD: Food and Drug Administration; 1998.
12. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. New York, NY: Springer; 1998.
13. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials. 2000;21:167-189.
14. Altman D. Practical Statistics for Medical Research. New York, NY: Chapman & Hall/CRC; 1991.
15. Chow S-C, Jen-Pei L. Design and Analysis of Clinical Trials: Concepts and Methodologies. New York, NY: John Wiley & Sons; 1998.
16. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
17. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64:191-200.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
19. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341-1352; discussion 53-56.
20. Daya S. Strategies to control confounding in causation studies. Evid Based Obstet Gynecol. 2002;4:1-2.
21. Toto RD, Adams-Huet B, Fenves AZ, et al. Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. Am J Kidney Dis. 1996;28:832-840.